Previous 10 | Next 10 |
– LINZESS ® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – ...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q1 earnings results on Thursday, May 6th, before market open.The consensus EPS Estimate is $0.21 (+425.0% Y/Y) and the consensus Revenue Estimate is $91.15M (+14.0% Y/Y).Over the last 2 years, IRWD has beaten EPS estimates 75% of...
[[ACIW]], [[ADNT]], [[AES]], [[AHCO]], [[ALE]], [[APTV]], [[ARW]], [[AVYA]], [[AZUL]], [[BDX]], [[BIP]], [[BKI]], [[BLD]], [[BLDR]], [[BLL]], [[BUD]], [[BV]], [[CAH]], [[CARS]], [[CNP]], [[COMM]], [[CORE]], [[CWEN]], [[DEN]], [[DLX]], [[DOCN]], [[ECOM]], [[EPAM]], [[EPC]], [[EPZM]], [[EVOP]],...
Biopharma company Alkermes (ALKS), which was targeted by activist investor Elliott Management last year, has reached an agreement with Sarissa Capital, giving the activist fund the right to designate a director for the company's board.The agreement follows "constructive" dialogue between...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 6, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and ...
After the failure of two development programs in 2020, Ironwood Pharmaceuticals, Inc. is without a clinical asset. The recent departure of the company’s CEO after the promotion of activist investor Alex Denner to its board has the investment community speculating that a sale is...
Biopharma company Alkermes (ALKS), which was targeted by activist investor Elliott Management last year, may face further pressure from another activist fund Sarissa Capital Management.Sarissa, led by Alex Denner, who at one time worked for Carl Icahn, is the biggest hedge fund owner of Alker...
The stock markets are experiencing a phase of volatility and uncertainty. Inflation fears and a potential tech bubble burst could precipitate a deep sell-off in the near-term. However, experts say that inflationary headwinds will abate by year’s end. In this scenario, we think it best ...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, announced that management will be presenting at the following investor conferences: SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:00 a.m. EST Cowen Annual Health Ca...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...